Você está na página 1de 10

Clinical Significance of Thrombocytopenia During a

Non–ST-Elevation Acute Coronary Syndrome


The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor
Suppression Using Integrilin Therapy (PURSUIT) Trial Experience
Matthew W. McClure, MD; Scott D. Berkowitz, MD; Rodney Sparapani, MS; Robert Tuttle, MSPH;
Neal S. Kleiman, MD; Lisa G. Berdan, PA-C, MHS; A. Michael Lincoff, MD; Jaap Deckers, MD;
Rafael Diaz, MD; Karl R. Karsch, MD; Daniel Gretler, MD; Michael Kitt, MD;
Maarten Simoons, MD; Eric. J. Topol, MD; Robert M. Califf, MD;
Robert A. Harrington, MD; for the PURSUIT Investigators

Background—The significance of thrombocytopenia in patients experiencing an acute coronary syndrome (ACS) has not
been examined systematically. We evaluated this condition in a large non–ST-elevation ACS clinical trial, with
particular interest paid to its correlation with clinical outcomes.
Methods and Results—Patients presenting without persistent ST elevation during an ACS were randomized to receive a
double-blind infusion of the platelet glycoprotein (GP) IIb/IIIa inhibitor eptifibatide or placebo in addition to other
standard therapies including heparin and aspirin. The primary end point was death/nonfatal myocardial infarction (MI)
at 30 days, whereas bleeding and stroke were the main safety outcomes. Thrombocytopenia (nadir platelet count
,1003109/L or ,50% of baseline) occurred in 7.0% of enrolled patients. The time to onset was a median of 4 days
in both treatment arms. Patients with thrombocytopenia were older, weighed less, were more likely nonwhite, and had
more cardiac risk factors. These patients experienced significantly more bleeding events: they were more than twice as
likely to experience moderate/severe bleeding after adjustment for confounders. Univariably, ischemic events (stroke,
MI, and death) occurred significantly (P,0.001) more frequently in patients with thrombocytopenia; multivariable
regression modeling preserved this association with death/nonfatal MI at 30 days. Neither the use of heparin or
eptifibatide was found to independently increase thrombocytopenic risk.
Conclusions—Although causality between thrombocytopenia and adverse clinical events could not be established
definitively, thrombocytopenia was highly correlated with both bleeding and ischemic events, and the presence of this
condition identified a more-at-risk patient population. (Circulation. 1999;99:2892-2900.)
Key Words: platelets n eptifibatide n glycoproteins n angina n myocardial infarction n coronary artery disease

T he short- and long-term consequences of coronary


artery disease and its most common manifestation, the
acute coronary syndrome (ACS; unstable angina and
Thrombolysis In Myocardial Infarction (TIMI) groups have
demonstrated that thrombocytopenia in patients experiencing
acute ST-elevation MI is associated with significant increases
myocardial infarction [MI]), are responsible for many in in-hospital mortality, bleeding, and total hospital stay and
deaths worldwide each year.1,2 Extensive clinical research major and minor hemorrhage, respectively.3,4 Large ACS
has sought to determine what therapies can improve patient clinical trials have found that thrombocytopenia in patients
outcomes with ACS, but less is known about what clinical undergoing high-risk angioplasty for an ACS correlates
entities are associated with worsening the already elevated significantly with worse clinical outcomes, such as death and
risk of these patients. MI.5–7
Data suggest that thrombocytopenia developing during an The large subgroup of ACS patients with non–ST-
ACS carries negative prognostic significance. The Thrombol- elevation MI and unstable angina, however, remains rela-
ysis and Angioplasty in Myocardial Infarction (TAMI) and tively unstudied with respect to thrombocytopenia. The

Received July 22, 1998; revision received March 2, 1999; accepted March 29, 1999.
From the Duke Clinical Research Institute (M.W.M., S.D.B., R.S., R.T., L.G.B., R.M.C., R.A.H.), Durham, NC; Methodist Hospital (N.S.K.), Houston,
Tex; Cleveland Clinic Foundation (A.M.L., E.J.T.), Cleveland, Ohio; Cardialysis (J.D.), Rotterdam, Netherlands; Estudios Cardiologicos Latinoamerica
(R.D.), Rosario, Argentina; Eberhard Karls University (K.R.K.), Tubingen, Germany; COR Therapeutics (D.G., M.K.), South San Francisco, Calif; and
Thoraxcenter University Hospital (M.S.), Rotterdam, Netherlands.
This study was supported by COR Therapeutics, Inc (South San Francisco, Calif) and Schering Plough Research Institute (Kenilworth, NJ).
Correspondence to Robert A. Harrington, MD, Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705. E-mail Harri019@mc.duke.edu
© 1999 American Heart Association, Inc.
Circulation is available at http://www.circulationaha.org

2892
Downloaded from http://circ.ahajournals.org/ by guest on March 17, 2016
McClure et al June 8, 1999 2893

Platelet Glycoprotein IIb/IIIa in Unstable Angina: Recep- found to have severe and profound thrombocytopenia were then
tor Suppression Using Integrilin Therapy (PURSUIT) trial reviewed individually, when possible, to verify the occurrence and
degree of reported thrombocytopenia.
evaluated the clinical efficacy and safety of the platelet
Additionally, several different thrombocytopenic populations
glycoprotein (GP) IIb/IIIa inhibitor eptifibatide in this were initially analyzed as the PURSUIT thrombocytopenia popula-
important patient population. tion. Each of these 3 groups experienced a platelet nadir that fulfilled
We examined thrombocytopenia in PURSUIT and sought the PURSUIT definition of thrombocytopenia, but they were differ-
to determine its incidence in this patient population, its ent in that the timing with respect to coronary bypass grafting, a
procedure that was expected to be a significant confounder, was
prognostic significance, and finally, whether antiplatelet ther-
considered. The 3 groups analyzed were: (1) patients who developed
apy through GP IIb/IIIa inhibition predisposes this population thrombocytopenia and never underwent CABG; (2) those who
to develop thrombocytopenia.8 experienced thrombocytopenia before CABG or who never under-
went CABG; and (3) those who developed thrombocytopenia regard-
Methods less of the presence or timing of CABG. In each of these analyses,
although the actual numbers varied, the overall trends in outcome
Patient Population variables were similar. We therefore concluded that thrombocytope-
The international, multicenter PURSUIT trial9 evaluated 10 948 nia affected outcomes in a uniform direction regardless of the
patients presenting with a non–ST-elevation ACS. Eligible pa- presence or timing of bypass grafting, and we elected to the use the
tients had ischemic chest pain symptoms within 24 hours of broadly defined third definition for our final PURSUIT thrombocy-
enrollment and met either prespecified ECG or cardiac enzyme topenic population.
requirements. Patients were excluded from study participation for
predisposition to bleeding, pregnancy, abnormal baseline labora- Clinical Outcomes
tory measurements (including platelet count ,1003109/L), or use Clinical events such as death and myocardial ischemia/MI were
of thrombolytics, other GP IIb/IIIa antagonists, or experimental documented on the case report form. Those interventions and clinical
drug therapies. events that occurred after the baseline hospitalization but within 30
days of enrollment were prospectively documented on a standard
Treatments 30-day form.
Patients were randomized in a double-blind fashion to receive either The primary efficacy outcome of the present study was the
intravenous eptifibatide (180 mg/kg bolus plus 2 mg z kg21 z min21 combined end point of death and nonfatal MI by 30 days after
infusion [high dose] or 180 mg/kg bolus plus 1.3 mg z kg21 z min21 randomization. This end point was adjudicated by an independent,
infusion [low dose]) or intravenous placebo control for 72 to 96 blinded Clinical Events Committee (CEC) using prespecified diag-
hours. Early in the trial, however, safety parameters for the high dose nostic criteria.9
of eptifibatide were within acceptable limits, and as specified by the
protocol, the low-dose arm was discontinued, with all subsequent Safety Outcomes
patients receiving the high-dose regimen or placebo. Safety outcomes for PURSUIT were CEC-adjudicated stroke; a
Concomitant use of aspirin, heparin, and other medications was calculated bleeding index, defined as [number of units of packed
left to the discretion of the individual investigators. For those red blood cells transfused1(observed drop in hematocrit/3)]; and
patients weighing ,70 kg and receiving intravenous unfractionated the incidence of bleeding based on the GUSTO definition of
heparin, the protocol suggested a weight-adjusted heparin-dosing bleeding severity.12 According to these criteria, severe bleeding
nomogram.10 It was recommended that patients who weighed .70 was defined as intracranial hemorrhage or a bleeding event that
kg receive a standard nonadjusted heparin dose (5000 U IV bolus– caused hemodynamic compromise and required intervention,
1000 U/h infusion). Transfusion guidelines were provided to all whereas moderate bleeding events were defined as those requiring
investigators to standardize transfusion usage.11 All decisions re- blood transfusion but not leading to hemodynamic compromise or
garding cardiac catheterization or revascularization (PTCA or need for an intervention.
CABG) were left to the individual investigators.
Statistics
Thrombocytopenia: Determination and Definition Continuous variables are presented as medians with 25th and 75th
Platelet count determinations were recommended at baseline, on a percentiles. Categorical data are displayed as an incidence (%).
daily basis during study-drug infusion, and at the investigator’s Differences in baseline characteristics and clinical/safety outcomes
discretion during the remainder of hospitalization. The case report between patients with and without thrombocytopenia were compared
form for all patients documented the baseline platelet count, #5 univariably with the median test for all reported medians and Pearson
platelet measurements during study-drug infusion, and 1 nadir x2 test for all reported incidences.
platelet count after study-drug infusion. Thrombocytopenia was Because the outcomes in this patient population were multifacto-
defined as a nadir platelet count of ,1003109/L or a relative rial, we performed multivariable regression to isolate certain vari-
reduction of the nadir platelet count to ,50% of baseline.3 Severe ables and assess their independent association with these outcomes.
and profound thrombocytopenia were defined as platelet nadirs
These variables are presented as ORs with 95% CIs. Four regression
,503109/L and ,203109/L, respectively.5
models were performed, 3 of which examined the contribution of
thrombocytopenia to moderate/severe bleeding, the primary end
Additional Platelet Information point, and death alone, respectively. To assess the independent
Periodic review of the blinded PURSUIT database indicated which contribution of thrombocytopenia to these various outcomes, the
study patients were experiencing thrombocytopenia. A standard model was adjusted for variables found to be important prognostic
thrombocytopenia form was then used to collect additional informa- factors in previous ACS trials,13 all statistically significant differ-
tion such as hematology consultations, heparin-induced antibody ences in baseline characteristics, the presence of a moderate/severe
determinations, and a complete listing of all platelet counts with bleeding event (except in the moderate/severe bleeding model),
regard to those patients who were experiencing severe or profound procedural interventions, and factors presumed to be important
thrombocytopenia. predictors of these outcomes. The fourth multivariable regression
model, which attempted to predict risk factors for thrombocytopenia,
PURSUIT Thrombocytopenia Population was created with disproportionately represented baseline character-
For purposes of this analysis, only data from the high-dose eptifi- istics, procedural interventions, and known or presumed thrombocy-
batide and placebo arms of PURSUIT were analyzed. Those patients topenia predictors used as covariates.

Downloaded from http://circ.ahajournals.org/ by guest on March 17, 2016


2894 Thrombocytopenia in Non–ST-Elevation ACS

TABLE 1. Incidence of Thrombocytopenia The Figure depicts the time to onset of thrombocytopenia for
Placebo Eptifibatide
the overall thrombocytopenia definition and the combined se-
Degree of Thrombocytopenia (n54603) (n54614) P vere/profound thrombocytopenia groups, respectively. In the
overall thrombocytopenia population, the timing of thrombocy-
,1003109/L or ,50% of baseline 319 (7.0%) 314 (6.9%) 0.794
topenia was nearly identical in the 2 treatment arms (4 [2, 7]
,1003109/L 227 (4.9%) 227 (4.9%) 0.979
days for placebo versus 4 [2, 8] days for eptifibatide). In the
,503109/L (severe thrombocytopenia) 18 (0.4%) 23 (0.5%) 0.438
combined severe/profound thrombocytopenia group, the curves
,203109/L (profound thrombocytopenia) 2 (,0.1%) 5 (0.1%) 0.258 diverged early, with eptifibatide-treated patients developing
thrombocytopenia at a median of 52 (32, 81) hours after
Results randomization and placebo-treated patients developing throm-
bocytopenia at a median of 126 (99, 293) hours.
The overall incidence of thrombocytopenia was 7.0%. There
was an even distribution of thrombocytopenia between the Baseline Characteristics
placebo- and eptifibatide-treated arms across all definitions of Patients with thrombocytopenia were older, weighed less, and
thrombocytopenia (Table 1). were more likely to not be white (Table 2). Additionally, they

Time to onset of thrombocytopenia for overall thrombocytopenia definition (top) and combined severe/profound thrombocytopenia
groups (bottom) for patients treated with eptifibatide (E) or placebo (P).

Downloaded from http://circ.ahajournals.org/ by guest on March 17, 2016


McClure et al June 8, 1999 2895

TABLE 2. Baseline Characteristics


No Platelet Nadir Platelet Nadir
Thrombocytopenia* Thrombocytopenia ,1003109/L $1003109/L
Characteristic (n5633) (n58468) P (n5454) (n58763)
Median age, y 67 (60, 73) 64 (55, 71) ,0.001 69 (62, 74) 64 (55, 71)
Male sex 62.1 64.6 0.201 63.4 64.5
Median weight, kg 76 (66, 87) 78 (69, 88) 0.014 76 (65, 86) 78 (69, 88)
White 85.6 89.3 0.004 87.6 89.0
Hypertension 57.8 55.1 0.181 57.0 55.2
Diabetes mellitus 26.7 22.7 0.020 24.4 22.8
Hypercholesterolemia 43.6 41.7 0.361 41.6 41.9
Tobacco use ,0.001
Current smoker 21.4 28.8 20.6 28.7
Former smoker 37.0 32.5 37.5 32.6
Never smoked 41.6 38.7 41.9 38.7
Family history of CAD 36.3 35.2 0.574 34.9 35.3
Peripheral vascular disease 11.9 8.0 0.001 12.1 8.1
Previous MI 37.8 32.1 0.003 39.4 32.2
Previous bypass surgery 11.7 11.9 0.849 13.2 11.9
Previous angioplasty 17.4 12.3 ,0.001 18.3 12.4
CAD indicates coronary artery disease.
All results are expressed as percentages except where indicated.
*Thrombocytopenia defined as platelet nadir ,1003109/L or a relative reduction of the nadir platelet count to
,50% of baseline.

had a greater number of cardiac risk factors, were more mic events (stroke, MI, death, and recurrent ischemia leading
frequently diabetic, and had a greater incidence of previous to cardiac procedure) at any point after enrollment was higher
MI, prior angioplasty, and history of peripheral vascular in patients with thrombocytopenia. The median length of stay
disease. in both intensive care units and during baseline hospitaliza-
tion was also significantly (P,0.001) longer for patients
Platelet Measures experiencing thrombocytopenia.
Although there was a significant (P,0.001) difference in
baseline platelet count between the thrombocytopenia Use of Antiplatelet Therapies
(2123109/L [1633109/L, 2603109/L]) and nonthrombocy- The use of abciximab (0.3% versus 0.2%; P50.435),
topenia groups (2263109/L [1923109/L, 2683109/L]), the ticlopidine (7.1% versus 9.6%; P50.041), aspirin (91.3%
total decrease in platelet count from baseline, as expected, versus 93.6%; P50.025), and thrombolytic therapy (2.1%
was more marked in the thrombocytopenia group versus 2.3%; P50.656)—all drugs with known or potential
(1273109/L [833109/L, 1643109/L] versus 293109/L antiplatelet effects—was similarly distributed between the
[133109/L, 513109/L] for nonthrombocytopenia). The thrombocytopenia and nonthrombocytopenia groups, re-
median absolute nadir platelet counts were 903109/L spectively. Heparin, also a drug with a known thrombocy-
(75310 9/L, 103310 9/L) and 193310 9/L (161310 9/L, topenic effect,14 was used with more prevalence (94.3%
2313109/L) for the thrombocytopenia and nonthrombocy- versus 89.6%; P,0.001) and was infused for a longer
topenia groups, respectively. period (87.0 versus 76.5 hours; P50.021) in the thrombo-
cytopenic group.
Transfusions/Bleeding Events
The development of thrombocytopenia was associated with a Eptifibatide Versus Placebo in
substantially higher incidence of any bleeding event, a Thrombocytopenic Patients
moderate/severe bleeding event, and the need for red blood A comparison of clinical events in the thrombocytopenic
cell or platelet transfusion at any point during baseline population of PURSUIT, grouped by study drug, revealed
hospitalization (Table 3). The bleeding index was also sig- a consistent but not statistically significant (except CABG,
nificantly higher (5.3 for thrombocytopenia versus 1.4 for P50.027) trend toward better clinical outcomes in patients
nonthrombocytopenia; P,0.001). with thrombocytopenia who were treated with eptifibatide
(Table 4). This relationship occurred in spite of an excess
Clinical Outcomes incidence of any bleeding (P50.017) and severe bleeding
Data at 30 days after randomization documented worse (P50.046) in this group. A formal statistical test for
outcomes for patients with thrombocytopenia than for those interaction in our primary end-point regression model
without thrombocytopenia (Table 3). The incidence of ische- confirmed no significant interaction between treatment
Downloaded from http://circ.ahajournals.org/ by guest on March 17, 2016
2896 Thrombocytopenia in Non–ST-Elevation ACS

TABLE 3. Safety/Clinical Outcomes


No Platelet Nadir Platelet Nadir
Thrombocytopenia† Thrombocytopenia ,1003109/L $1003109/L
Variable* (n5633) (n58468) P (n5454) (n58763)
Safety outcomes
Incidence of bleeding (all) 75.8 27.8 ,0.001 73.8 28.9
Severe bleeding 7.7 0.7 ,0.001 9.0 0.8
Moderate bleeding 48.2 7.5 ,0.001 45.8 8.5
Transfusions (whole blood or PRBC)
Incidence 55.6 7.4 ,0.001 54.0 8.5
Median U/pt 1 (0, 4) 0 (0, 0) ,0.001 1 (0, 4) 0 (0, 0)
.2 U/pt 34.1 3.1 ,0.001 35.7 3.6
Platelet transfusions 19.6 1.2 ,0.001 21.6 1.5
Median bleeding index 5.3 (2.6, 7.0) 1.4 (0.7, 2.4) ,0.001 5.0 (2.3, 7.1) 1.4 (0.7, 2.4)
Stroke (by 30 days) 3.0 0.6 ,0.001 3.1 0.6
Ischemic 2.7 0.5 2.9 0.5
Hemorrhagic 0.16 0.05 0.20 0.0
Hemorrhagic conversion 0.0 0.04 0.0 0.0
Clinical outcomes (at 30 days)
Mortality 7.4 3.3 ,0.001 8.1 3.4
MI 27.2 12.2 ,0.001 26.7 12.6
Primary end point ‡ 30.0 14.1 ,0.001 30.2 14.4
Percutaneous procedure 11.2 27.0 ,0.001 12.1 26.6
Bypass surgery 70.3 11.6 ,0.001 65.9 13.1
Rehospitalization 9.5 12.4 0.034 10.2 12.3
Recurrent ischemia leading to 22.4 12.8 ,0.001 22.2 13.0
cardiac procedure
Median ICU stay, d 5 (3, 8) 3 (2, 5) ,0.001 5 (3, 8) 3 (2, 5)
Median baseline hospitalization, d 12 (8, 20) 8 (5, 12) ,0.001 12 (8, 19) 8 (5, 13)
PRBC indicates packed red blood cells; pt, patient; and ICU, intensive care unit.
*Events both before and after onset of thrombocytopenia. Results expressed as percentages except where indicated.
†Thrombocytopenia defined as platelet nadir ,1003109/L or a relative reduction of the nadir platelet count to ,50% of baseline.
‡Combined incidence of death and nonfatal MI at 30 days.

group and thrombocytopenia, implying that the benefit (OR 12.2 [9.1 to 16.2]), as were patients with moderate to
seen in the overall PURSUIT trial occurred in the same severe bleeding events and those treated with an intra-aortic
direction and with similar magnitude for the thrombocy- balloon pump. However, the use of heparin, a therapy well
topenia subpopulation. known to cause thrombocytopenia,14 did not significantly
predispose patients to increased thrombocytopenic risk in our
Regression Models model when evaluated dichotomously (heparin use: yes/no;
The multivariable regression model for predictors of moder- exposure time: ,5 days/$5 days) and continuously (infusion
ate/severe bleeding (Table 5) demonstrated that even after duration). Similarly, the use of other antiplatelet therapies (ie,
adjustment for confounders, thrombocytopenia was indepen- aspirin, ticlopidine, abciximab, thrombolytics, and eptifi-
dently correlated with an increased bleeding risk (OR 2.0 [1.6 batide) was not associated with a significantly increased risk
to 2.6]). Similarly, the model for predictors of the PURSUIT of thrombocytopenia.
primary end point (Table 5) revealed that thrombocytopenia
was independently associated with an increased rate (OR 1.3 Discussion
[1.0 to 1.6]) of death/nonfatal MI within 30 days of random- The data (Table 3) suggest a clear correlation between
ization, even after adjustment for a large number of con- thrombocytopenia and adverse clinical outcomes including
founding variables. Thrombocytopenia did not significantly serious bleeding and ischemic events. Although baseline
increase the risk of death alone, however, in our third characteristics of the thrombocytopenia population appear
regression model (not shown). to predispose this population to poorer outcomes, our
Finally, a number of variables were found to correlate analysis shows that even after controlling for a number of
independently with increased risk of thrombocytopenia (Ta- these differences and other confounders (Table 5), the
ble 6). Patients who underwent CABG were highly signifi- isolated occurrence of thrombocytopenia remains signifi-
cantly predisposed to the development of thrombocytopenia cantly correlated with an increased incidence of moderate/
Downloaded from http://circ.ahajournals.org/ by guest on March 17, 2016
McClure et al June 8, 1999 2897

TABLE 4. Safety/Clinical Outcomes: Eptifibatide vs TABLE 6. Multivariable Regression Model: Variables


Placebo Thrombocytopenia Independently Associated with Thrombocytopenia*
Eptifibatide Placebo Variable† OR (95% CI) x2
Thrombocytopenia† Thrombocytopenia† CABG during baseline hospitalization 12.2 (9.1, 16.2) 289
Outcome* (n5314) (n5319)
Moderate/severe bleeding 2.4 (1.9, 3.2) 42
Any bleeding 80.0% 71.8%
Intra-aortic balloon pump 2.2 (1.5, 3.2) 16
Severe bleeding 9.9% 5.6%
Female sex 1.4 (1.1, 1.8) 6
Any RBC transfusion 58.3% 53.0%
History of PTCA 1.4 (1.0, 1.8) 4
Mortality 6.7% 8.2%
Age (increasing in 10-year increments) 1.2 (1.1, 1.3) 9
MI 23.9% 30.4%
Eptifibatide 1.0 (0.8, 1.3) 0.03
Percutaneous procedure 11.1% 11.3%
Baseline platelet count (decreasing by 1.05 (1.04, 1.06) 24
CABG 66.2% 74.3% 103109/L)
Stroke 2.9% 3.1% *Thrombocytopenia defined as platelet nadir ,1003109/L or a relative
Incidence of rehospitalization 9.0% 10.1% reduction of the nadir platelet count to ,50% of baseline.
Recurrent ischemia leading to 21.0% 23.8% †Variables include events that occurred before and after onset of thrombo-
a cardiac procedure cytopenia. Variables listed are those in the model with P,0.05 and OR .1.0
plus eptifibatide and baseline platelet count.
Median ICU stay, d 5.0 (3.0, 8.0) 5.0 (3.0, 8.0)
Median baseline 12.0 (8.0, 20.0) 12.0 (8.0, 20.0)
hospitalization stay, d correlates with ischemic events such as MI, stroke, and
RBC indicates red blood cell; ICU, intensive care unit. recurrent ischemia, because these outcomes are widely
*Events both before and after onset of thrombocytopenia. All events occurred regarded as platelet-mediated events. These findings sug-
within 30 days of randomization except bleeding, which occurred only during
gest that the observed platelet decline might be linked with
baseline hospitalization.
†Thrombocytopenia defined as platelet nadir ,1003109/L or a relative clinically significant thrombosis. Regardless, the strength
reduction of the nadir platelet count to ,50% of baseline. of the findings in PURSUIT, in combination with the
consistently similar findings in the ST-elevation (TAMI3
severe bleeding and death/MI at 30 days. The physiology and TIMI4), high-risk angioplasty (EPIC5), and broadly
of primary hemostasis makes the finding of increased defined ACS populations (ESSENCE6 and GUSTO IIb7),
bleeding risk and need for transfusions in thrombocytope- is very suggestive of the prognostic importance of
nic patients intuitive, but it is less clear why this condition thrombocytopenia.

TABLE 5. Multivariable Regression Models: Role of Thrombocytopenia in


Moderate/Severe Bleeding and Death/MI at 30 days
Variable† OR (95% CI) x2
Model A: Moderate/severe bleeding*
CABG during baseline hospitalization 63.7 (49.8, 81.5) 1090
Eptifibatide 3.4 (1.1, 11.1) 4
Intra-aortic balloon pump 3.3 (2.3, 5.0) 36
PTCA during baseline hospitalization 2.6 (2.0, 3.3) 48
Thrombocytopenia ‡ 2.0 (1.6, 2.6) 29
Intravenous b-blocker use 1.6 (1.1, 2.4) 6
Female sex 1.6 (1.2, 2.3) 8
Model B: Death/MI* at 30 days
Intra-aortic balloon pump 3.1 (2.3, 4.2) 56
Moderate/severe bleeding* 2.0 (1.6, 2.5) 41
CABG during baseline hospitalization 1.8 (1.5, 2.3) 29
Qualifying MI 1.7 (1.5, 1.9) 65
PTCA during baseline hospitalization 1.7 (1.4, 2.0) 37
Rales on physical examination 1.5 (1.2, 1.8) 17
Thrombocytopenia ‡ 1.3 (1.0, 1.6) 4
*Outcome events (moderate/severe bleeding, death/MI) include those events that occurred before
and after onset of thrombocytopenia.
†Variables listed are those in the models with P,0.05 and OR .1.5 and eptifibatide (Model A) and
thrombocytopenia (Model B).
‡Thrombocytopenia defined as platelet nadir ,1003109/L or a relative reduction of the nadir
platelet count to ,50% of baseline.

Downloaded from http://circ.ahajournals.org/ by guest on March 17, 2016


2898 Thrombocytopenia in Non–ST-Elevation ACS

Definition of Thrombocytopenia associated with the condition because of a combination of


Although the ,50% of baseline component of our definition mechanical consumption, hemodilution, platelet filtering,
of thrombocytopenia is not often included in analyses of and qualitative platelet alteration16; and, as our model
thrombocytopenia, we felt its inclusion was important be- shows (Table 6), patients who have undergone CABG are
cause these reductions indicate a degree of platelet compro- .12 times as likely to develop thrombocytopenia as
mise that is potentially clinically significant. Importantly, in patients who never underwent CABG. The use of intra-
addition to comparing baseline characteristics and safety/ aortic assist devices, thought to cause thrombocytopenia
clinical outcomes for our definition of thrombocytopenia, mainly through mechanical trauma,16 was also found to
Tables 2 and 3 also provide a breakdown of thrombocytope- more than double risk of thrombocytopenia (OR 2.2 [1.5 to
nia with a definition of a platelet nadir ,1003109/L. These 3.2]).
data are provided to facilitate comparison with already Several nonsurgical interventions predispose a patient to
published data and also underscore how similar the ,50% of thrombocytopenia as well. One such intervention, heparin
baseline component of our population was to the traditionally therapy, is associated with thrombocytopenia via 2 mech-
defined ,1003109/L portion. anisms: an immune-dependent, heparin-induced thrombo-
cytopenia (HIT), which is mediated by antiplatelet anti-
Incidence of Thrombocytopenia bodies, and a separate nonimmune mechanism. 1 4
We observed a 7.0% overall incidence of thrombocytopenia Consistent with this fact, univariably, we found a doubling
(platelet nadir ,1003109/L or relative reduction to ,50% of of thrombocytopenic risk (P50.001) in PURSUIT patients
baseline) in the non–ST-segment-elevation population of who were exposed to heparin therapy. Furthermore, the
PURSUIT. This incidence is lower than that observed in the thrombocytopenia population was more likely to receive
acute MI, thrombolytic-treated populations studied by the heparin and for a longer duration than were patients
TAMI group (16.4%), which used the same definition of without thrombocytopenia. When examined univariably,
thrombocytopenia,3 and is higher than that in TIMI-I (4.8%), however, heparin use is also confounded by procedural
which broadly defined thrombocytopenia as a platelet nadir use, which by itself is associated with thrombocytopenia.
,1503109/L.15 Therefore, to assess the independent contribution of hep-
In ACS clinical trials in which published data exist to arin to thrombocytopenia, we performed the regression
define thrombocytopenia as a platelet nadir ,1003109/L, the model shown in Table 6, attempting to control for proce-
range of incidence of thrombocytopenia narrows consider- dures as well as other potentially confounding variables. In
ably. In PURSUIT and EPIC, the incidences of this more this model, we found that heparin was no longer associated
conservatively defined thrombocytopenia were 4.9% and with increased thrombocytopenic risk, regardless of
3.9%, respectively.5 In GUSTO IIb,7 ESSENCE,6 the groups whether heparin was measured as a dichotomous (heparin
studied by TAMI,3 and the conservative arm of TIMI II,4 the use: yes/no) variable or a continuous (infusion duration:
rates of thrombocytopenia by this same definition were 1.0%, hours) variable.
3.0%, 7.3%, and 1.5%, respectively. The overall range of It is not entirely surprising that the use of heparin in our
thrombocytopenia across these 6 large ACS clinical trials model was not significantly associated with the immune
thus becomes 1.0% to 7.3%. When one allows for differences type of HIT. Typically, without recent exposure (ie, within
in baseline characteristics in the patient populations, duration the last 2 months), .4 days of heparin therapy is required
and frequency of platelet monitoring, and varying incidences to precipitate immune-mediated (type II) HIT.14,17 The
of procedure use among these studies, this range likely PURSUIT population, however, had a median heparin
represents a reasonable estimate of the incidence of throm- exposure time of only 3.6 (2.3, 5.9; thrombocytopenia)
bocytopenia that can be expected in a given ACS clinical days and 3.2 (2.0, 4.5; nonthrombocytopenia) days and
trial. thus would not be expected to manifest significant num-
bers of type II HIT. We also compared thrombocytopenic
Timing of Thrombocytopenia risk in patients exposed to heparin for $5 days with those
The median time to development of thrombocytopenia was exposed for ,5 days. Again, we found no increase in the
4 days. This is equivalent to the timing seen in TAMI3 but risk of developing thrombocytopenia in heparin-exposed
longer than that seen in the more invasively treated patients, even with prolonged durations of heparin therapy
high-risk angioplasty population of EPIC (1.68 days for (OR 1.0 [0.8,1.2]).
placebo versus 0.5 days for abciximab).5 Timing data are Type I HIT, however, is characterized by mild declines in
unpublished in most other studies of thrombocytopenia the platelet count (10% to 20%), with nadir platelet counts
during an ACS, which makes it difficult to infer the that usually exceed 1003109/L and onset within 4 days of
universality of the observed PURSUIT median time to heparin exposure.14 This disorder is not thought to have
thrombocytopenia. clinical significance. It is possible that some patients in
PURSUIT developed type I HIT.
Origin of Thrombocytopenia Other medications thought or known to have antiplatelet
The treatment of patients experiencing an ACS involves a effects were relatively evenly distributed between thrombo-
complex mixture of pharmacological and surgical inter- cytopenic and nonthrombocytopenic patients. Consistent with
ventions that together can obscure the underlying cause of this observation was the nonsignificant impact all of these
a bout of thrombocytopenia. Cardiopulmonary bypass is drugs had on our model that predicted thrombocytopenia. It is

Downloaded from http://circ.ahajournals.org/ by guest on March 17, 2016


McClure et al June 8, 1999 2899

possible, however, that the total numbers involved (especially platelet counts during the initial 72 to 96 hours of enrollment,
with abciximab, ticlopidine, and thrombolytics) were inade- only 1 platelet count determination was recorded after infu-
quate to provide power to detect the potential contribution of sion of the study drug. Consequently, it is not possible to
these medications to risk of thrombocytopenia. address several important questions, such as total thrombo-
A recent meta-analysis of thrombocytopenic risk in the cytopenia duration and the time course to complete platelet
context of GP IIb/IIIa inhibition supports the concern that this recovery.
new class of drug may predispose patients to develop throm-
bocytopenia.8 Our data (Table 1) show a nearly identical Conclusions
distribution of thrombocytopenia between eptifibatide- and Nearly 1 in 14 patients with a non–ST-elevation ACS
placebo-treated arms in all severities of thrombocytopenia enrolled in the PURSUIT trial experienced thrombocytope-
except profound thrombocytopenia, and even in this group nia, defined as a platelet nadir ,1003109/L or ,50% of
the difference did not reach statistical significance baseline. Our analysis demonstrates that this large subset of
(P50.258). However, 5 of the 7 patients in this group were patients with unstable angina or non–Q-wave MI is at a
treated with eptifibatide, and time to onset of thrombocyto- significantly increased risk of experiencing not only serious
penia in eptifibatide-treated patients with severe/profound bleeding events (moderate/severe bleeding, need for red
thrombocytopenia diverges from placebo-treated patients blood cell/platelet transfusion) but clinically significant is-
quite early (Figure), leaving room for speculation that in this chemic events (death, nonfatal MI, stroke, recurrent ischemia
small subset of patients with thrombocytopenia, eptifibatide leading to a cardiac procedure) as well. Because causation
exposure could contribute to thrombocytopenic risk. Even if could not be established between thrombocytopenia and
this were true, however, only a very small subset of patients outcomes, it would be inappropriate to infer from this
(0.1% of all patients treated) would be at risk of developing analysis that prophylactic platelet transfusions should be
this condition, whereas the vast majority of non–ST-elevation administered to patients experiencing thrombocytopenia in an
ACS patients appear to be at an equal risk of developing attempt to decrease their risk of morbidity and mortality.
thrombocytopenia regardless of eptifibatide exposure. This Further study is warranted, however, to refine the estimate of
statement is substantiated by our regression model (Table 6), magnitude of the effect of thrombocytopenia on outcomes
which does not indicate any significant contribution of and to better examine its causes. In the meantime, daily
eptifibatide to thrombocytopenia after controlling for con- platelet count determinations should be collected in all
founders. More importantly, in general, except perhaps for patients experiencing an ACS to aid in early identification of
this group of patients with profound thrombocytopenia, this important at-risk patient population.
patients with thrombocytopenia who receive eptifibatide ap-
pear to benefit from its use, just as they do in the overall Acknowledgments
PURSUIT population.9 This conclusion is implied by the This study was supported by COR Therapeutics, Inc (South San
Francisco, Calif) and Schering Plough Research Institute (Ken-
consistent but small trend toward fewer adverse events ilworth, NJ). The authors wish to thank Gail Tudor, PhD, for her
(except bleeding) in the eptifibatide-treated thrombocytope- thoughtful review and insights into the contents of this manuscript.
nic population (Table 4) and the absence of a significant Additionally, we are grateful to Penny Hodgson and John Daniel for
treatment-by-thrombocytopenia interaction term in our pri- their editorial expertise in drafting this manuscript.
mary end-point regression model.
References
1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the
Limitations world: Global Burden of Disease Study. Lancet. 1997;349:1269 –1276.
Our analysis clearly points toward a correlation between 2. American Heart Association. 1997 Heart and Stroke Statistical Update.
thrombocytopenia and adverse events but cannot be inter- Dallas, Tex: American Heart Association; 1997:2–29.
preted to establish causation. Some events preceded the 3. Harrington RA, Sane DC, Califf RM, Sigmon KN, Abbottsmith CW,
Candela RJ, Lee KL, Topol EJ, for the TAMI Study Group. Clinical
development of thrombocytopenia (eg, MI in Table 3) and importance of thrombocytopenia occurring in the hospital phase after
therefore cannot be included in a model to establish the administration of thrombolytic therapy for acute myocardial infarction.
predictive (causal) power of thrombocytopenia on negative J Am Coll Cardiol. 1994;23:891– 898.
outcomes. To establish such a model, one must include only 4. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D,
Feit F, Gore JM, Hillis D, Lambrew CT, Leiboff R, Mann KG, Markis JE,
those events that can be shown to have occurred after the Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH, for the TIMI
onset of thrombocytopenia. Because of the nature of our Investigators. Hemorrhagic events during therapy with recombinant
timing data, only death, which by definition cannot be tissue-type plasminogen activator, heparin, and aspirin for acute myo-
cardial infarction. Ann Intern Med. 1991;115:256 –265.
followed by events such as thrombocytopenia, is eligible for 5. Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA,
such a predictive model. Our regression model for predicting Tcheng JE, Topol EJ, Califf RM, for the EPIC Study Group. Occurrence
death (not shown) failed to demonstrate an increased inci- and clinical significance of thrombocytopenia in a population undergoing
dence of death in patients with thrombocytopenia, however. high-risk percutaneous coronary revascularization. J Am Coll Cardiol.
1998;32:387–392.
Whether this observation reflects a lack of a causal role of 6. Berkowitz SD, Sparapani RA, Califf RM, Cohen M. Occurrence and
thrombocytopenia on death or simply the low incidence of significance of thrombocytopenia in unstable angina and non-Q-wave
death in the trial is difficult to establish. infarction in the ESSENCE trial. Blood. 1997;90:81b. Abstract.
7. Berkowitz SD, Granger CB, Thompson T, Kleiman NS, Topol EJ, Califf
A second limitation of this study is the amount of platelet
RM. Thrombocytopenia was associated with greater hemorrhage and
count data collected during baseline hospitalization. Although higher mortality in GUSTO IIb trial. Thromb Haemost. 1997;236:PS-962.
the case report form allowed documentation of up to 5 Abstract.

Downloaded from http://circ.ahajournals.org/ by guest on March 17, 2016


2900 Thrombocytopenia in Non–ST-Elevation ACS

8. Giugliano RP, Hyatt RR Jr. Thrombocytopenia with GP IIb/IIIa inhibi- determined by baseline clinical factors. J Am Coll Cardiol. 1999;
tors: a meta-analysis. J Am Coll Cardiol. 1998;31:185A. Abstract. 33:359A. Abstract.
9. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa 14. Brieger DB, Mak KH, Kottke-Marchant C, Topol EJ. Heparin-induced
with eptifibatide in patients with acute coronary syndromes. N Engl thrombocytopenia. J Am Coll Cardiol. 1998;31:1449 –1459.
J Med. 1998;339:436 – 443. 15. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR,
10. Wali AU, Gavrila D, Sim MJ, Malhotra S, Palazzo AM, Hochman JS. An Knatterud G, Robertson TL, Terrin ML, for the TIMI Investigators.
improved regimen for heparin use in acute coronary syndromes. Circu- Hemorrhagic manifestations and changes in plasma fibrinogen and the
lation. 1997;96(suppl I):I-597. Abstract. fibrinolytic system in patients treated with recombinant tissue plas-
11. American College of Physicians. Practice strategies for elective red blood minogen activator and streptokinase. J Am Coll Cardiol. 1988;
cell transfusion. Ann Intern Med. 1992;116:403– 406. 11:1–11.
12. The GUSTO Investigators. An international randomized trial comparing 16. Robblee JA. Platelet utilization in cardiopulmonary bypass surgery. Curr
four thrombolytic strategies for acute myocardial infarction. N Engl Stud Hematol Blood Transfus. 1988;54:101–106.
J Med. 1993;329:673– 682. 17. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M,
13. Boersma E, Pieper K, Wilcox RG, Steyerberg E, Lee KL, Akkerhuis M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with
Harrington RA, Califf RM, Simoons ML. The risk of adverse outcome in low-molecular-weight heparin or unfractionated heparin. N Engl J Med.
patients with acute coronary syndromes without ST-elevation is mainly 1995;332:1330 –1335.

Downloaded from http://circ.ahajournals.org/ by guest on March 17, 2016


Clinical Significance of Thrombocytopenia During a Non−ST-Elevation Acute Coronary
Syndrome: The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression
Using Integrilin Therapy (PURSUIT) Trial Experience
Matthew W. McClure, Scott D. Berkowitz, Rodney Sparapani, Robert Tuttle, Neal S. Kleiman,
Lisa G. Berdan, A. Michael Lincoff, Jaap Deckers, Rafael Diaz, Karl R. Karsch, Daniel Gretler,
Michael Kitt, Maarten Simoons, Eric. J. Topol, Robert M. Califf and Robert A. Harrington
for the PURSUIT Investigators

Circulation. 1999;99:2892-2900
doi: 10.1161/01.CIR.99.22.2892
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1999 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/99/22/2892

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:


http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:


http://circ.ahajournals.org//subscriptions/

Downloaded from http://circ.ahajournals.org/ by guest on March 17, 2016

Você também pode gostar